Cập nhật lần cuối :
28/04/2024
Thuốc ức chế bơm proton   Pantoprazole sodium  
Dạng tiêm
Dung dịch uống
Tính ổn định của các dung dịch Độ ổn định khi trộn lẫn Những yếu tố ảnh hưởng đến độ ổn định Khả năng tương thích Đường dùng Tài liệu tham khảo Pdf
   Cấu trúc hóa học  

Tên thương mại   Tên thương mại     

Các tên thương mại được cung cấp và thành phần tá dược có thể khác nhau giữa các quốc gia và các hãng dược

Acinil Peru
Anagastra Tây Ban Nha
Anetrum Argentina
Belpan Ấn Độ
Controloc Ả Rập, Ba Lan, Croatia, Hungary, Hy Lạp, Malaysia, Romania, Slovenia
Dazol Ấn Độ
Dole Ấn Độ
Ducopan Ấn Độ
Dunapan Ấn Độ
Emzole Ấn Độ
Epant Ấn Độ
Eracid Ấn Độ
Eupantol Pháp
Flumetax Peru
Gastrazol
Inipomp Pháp
Pangest Ả Rập Saudi
Panto Canada
Pantoc Bồ Đào Nha
Pantoloc Áo, Thụy Điển, Đan Mạch
Pantoprazol Chile, Đức
Pantorc Ý
Pantozol Ả Rập Saudi, Bỉ, Thụy Sỹ, Đức
Pantpas Thổ Nhĩ Kỳ
Protium Anh
Protonix Hoa Kỳ
Segregam Colombia
Somac Na Uy, Phần Lan, Úc
Zurcal Colombia, Thụy Sỹ
Zurcazol Hy Lạp
Tài liệu tham khảo   Dạng tiêm   Tài liệu tham khảo : Pantoprazole sodium  
Loại Nguồn
1506 Tạp chí Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D.
Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units.
EJHP 2015 ;22:107-112.
1508 Tạp chí Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
1902 Tạp chí Walker SE, Wyllie A, Law S.
Physical compatibility of pantoprazole with selected medications during simulated Y-site administration.
Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1982 Tạp chí Trissel LA, Ogundele AB.
Compatibility of anidulafungin with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2005 ; 62: 834-837.
2030 Tạp chí Johnson CE.
Stability of pantoprazole in 0.9% sodium chloride injection in polypropylene syringes.
Am J Health-Syst Pharm 2005 ; 62: 2410-2412.
2090 Tạp chí Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2139 Tạp chí Serrurier C, Chenot ED, Vigneron J, May I, Demor? B.
Assessment of injectable drug’s administration in two intensive care units and determination of potential physico-chemical incompatibilities.
EJHP Science 2006 ; 12,5: 96-99.
2233 Tạp chí Condie C.K, Tyler L.S, Barker B, Canann D.M.
Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery
Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247 Tạp chí Chan P, Heatherly K, Kupiec T.C, Trissel L.A.
Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262 Tạp chí Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Tạp chí Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2311 Tạp chí Kambia N.K, Luyckx M, Dine T, Dupin-Spriet T, Gressier B, Brunet C.
Nefopam hydrochloride compatibility and stability with selected proton pump inhibitors in bionolyte G5 injection for intravenous infusion.
J Clin Pharm Ther 2009 ; 34: 25-31.
2337 Tạp chí Walker S.E, Iazzetta J, Law S.
Extended Stability of Pantoprazole for Injection in 0.9% Sodium Chloride or 5% Dextrose at 4°C and 23°C
Can J Hosp Pharm 2009 ; 62, 2: 135-141.
3012 Tạp chí Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3216 Tạp chí Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3220 Tạp chí Donnelly RF.
Stability of Pantoprazole Sodium in Glass Vials, Polyvinyl Chloride Minibags, and Polypropylene Syringes.
Can J Hosp Pharm 2011 , 64, 32: 192-198.
3249 Tạp chí Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254 Tạp chí Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.
Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration
Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408 Tạp chí Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3429 Tạp chí Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S.
Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration
Am J Health-Syst Pharm 2015 ; 72:483-486
3728 Tạp chí Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3767 Tạp chí Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3791 Poster Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.
Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y.
Apifh Congress, Paris November 2014 2014
3824 Tạp chí Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.
Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.
ASHP Midyear 2015
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.
Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.
ASHP Midyear 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.
Compatibility of isavunazonium sulfate during simulated Y-site administration.
ASHP Midyear 2015
3948 Tạp chí Bouchoud L, Fonzo-Christe C, Klingm?ller M, Bonnabry P .
Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation.
JPEN 2012 ;30. 416?424.
3964 Tạp chí Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
3976 Tạp chí Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055 Tạp chí Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.
Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Tạp chí Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.
Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4254 Tạp chí D'Huart E, Vigneron J, Demoré B.
Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs
Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4316 Tạp chí Carpenter J.F, McNulty M-A, Dusci L.J, Ilett K.F.
Stability of Omeprazole Sodium and Pantoprazole Sodium Diluted for Intravenous Infusion.
J Pharm Technol 2006 ;22:95-98.
4319 Tạp chí Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4433 Tạp chí Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K.
Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications
Clin Ther 2020 ; 42, 3: 475-485.
4434 Tạp chí Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.
Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration.
Clin Ther 2019 ; 41, 10: 2162-2170.
4521 Tạp chí Polo C, D’Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B.
Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit.
Pharmaceutical Technology in Hospital Pharmacy 2020
4528 Tạp chí Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N.
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.
Int J Pharm Compound 2021 ;25,1:52-61
4650 Thông tin của nhà sản xuất Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4654 Poster Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R.
Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables.
Communication personnelle 2021
4655 Tạp chí Holyk A, Lindner A, Lindner S, Shippert B
Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration.
Am J Health-Syst Pharm 2022 ;79,1:27-33
4698 Tạp chí Ayari G, D'Huart E, Vigneron J, Demoré B.
Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs.
Pharmaceutical Technology in Hospital Pharmacy 2022
4742 Tạp chí Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales